Rebecca Germino
Overview
Explore the profile of Rebecca Germino including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
526
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wright G, Mysler E, Kwok K, Cadatal M, Germino R, Yndestad A, et al.
Rheumatol Ther
. 2024 Jul;
11(5):1135-1164.
PMID: 38958913
Introduction: Racial disparities in disease activity, clinical outcomes, and treatment survival persist despite advancements in rheumatoid arthritis (RA) therapies and clinical management. In this post hoc analysis of pooled data...
2.
Pappas D, OBrien J, Moore P, Dodge R, Germino R, Masri K, et al.
J Rheumatol
. 2024 Feb;
51(5):452-461.
PMID: 38359941
Objective: This real-world analysis assessed baseline demographics/characteristics and treatment patterns/effectiveness in patients with rheumatoid arthritis (RA) initiating tofacitinib (TOF) in the US CorEvitas RA Registry. Methods: The primary analysis of...
3.
McErlane F, Boeri M, Bussberg C, Cappelleri J, Germino R, Stockert L, et al.
Pediatr Rheumatol Online J
. 2023 Oct;
21(1):129.
PMID: 37865801
Background: This study aimed to elicit and quantify preferences for treatments for juvenile idiopathic arthritis (JIA). Methods: We conducted a discrete-choice experiment among adolescents with JIA in the United States...
4.
Mease P, Young P, Gruben D, Fallon L, Germino R, Kavanaugh A
Adv Ther
. 2022 Apr;
39(6):2932-2945.
PMID: 35482248
Introduction: This study characterized real-world demographic and baseline clinical characteristics, as well as treatment persistence and adherence, in patients with psoriatic arthritis (PsA) who had newly initiated tofacitinib treatment. Methods:...
5.
Taylor P, Bushmakin A, Cappelleri J, Young P, Germino R, Merola J, et al.
J Dermatolog Treat
. 2022 Apr;
33(5):2614-2620.
PMID: 35385361
Objectives: Evaluate relationships between changes in dermatologic assessments and quality of life (QoL) measures; quantify dermatologic symptom severity impacts on QoL in patients with psoriatic arthritis (PsA) treated with tofacitinib....
6.
Lees C, Deuring J, Chiorean M, Daperno M, Bonfanti G, Germino R, et al.
Therap Adv Gastroenterol
. 2022 Feb;
14:17562848211054710.
PMID: 35154388
Introduction: Tofacitinib is an oral, small molecule Janus kinase inhibitor for the treatment of ulcerative colitis (UC). Outcome prediction based on early treatment response, along with clinical and laboratory variables,...
7.
Ytterberg S, Bhatt D, Mikuls T, Koch G, Fleischmann R, Rivas J, et al.
N Engl J Med
. 2022 Jan;
386(4):316-326.
PMID: 35081280
Background: Increases in lipid levels and cancers with tofacitinib prompted a trial of major adverse cardiovascular events (MACE) and cancers in patients with rheumatoid arthritis receiving tofacitinib as compared with...
8.
Taylor P, Bushmakin A, Cappelleri J, Young P, Germino R, Merola J, et al.
J Clin Med
. 2021 Sep;
10(18).
PMID: 34575192
Patients with psoriatic arthritis (PsA) experience impaired health-related quality of life (HRQoL). Tofacitinib is an oral Janus kinase inhibitor for the treatment of PsA, which has been associated with improvements...
9.
Cohen S, Pope J, Haraoui B, Mysler E, Diehl A, Lukic T, et al.
RMD Open
. 2021 Jun;
7(2).
PMID: 34103405
Objectives: To report the efficacy, safety and patient-reported outcome measures (PROs) of tofacitinib modified-release 11 mg once daily plus methotrexate in patients with rheumatoid arthritis (RA) from the open-label phase...
10.
Giles J, Ogdie A, Gomez Reino J, Helliwell P, Germino R, Stockert L, et al.
RMD Open
. 2021 Jan;
7(1).
PMID: 33452181
Objectives: This post-hoc analysis explored the impact of body mass index (BMI) on tofacitinib efficacy/safety in patients with active psoriatic arthritis (PsA). Methods: Data were pooled from two phase 3...